Efficacy of Anti-tubulin drug ( Paclitaxel ) as a single treatment and its combination with the commercially used drug metronidazole in the treatment of Giardiasis in the experimentally infected mice

Giardia infection is still a medical problem in the world as yet; it is the first cause of intestinal diarrhea and its consequences. The reliance on metronidazole as a basic treatment remains despite its side effects, especially when used for longer periods due to recurring infections, so research is ongoing to find participant for metronidazole in the treatment of giardia and at the same time works to limit its side effects. Cancer patients were shown to be 1.24 fold more susceptible and were at a higher risk of infection, which should alert physicians to the possible consequences. The study represents a step to lighten the burden on cancer patients who more exposed to Giardia infection. The importance of the participation of the Paclitaxel in the therapeutic protocol, developing anti-giardial compound that target the cell division machineries of the parasite, and reduce the genotoxicity effects of metronidazole. the dual treatment (metronidazole with Paclitaxel combination), yield a significant reduction in the percentage of IgA and IgG antibodies indicating an increase in the evanescence of the antigens that stimulate the production of antibodies. It is true that the dual treatment gave less removal of the number of eggs in the stool, as well as the trophozoite than metronidazole alone, but it gave better disappearance of the pathogens which stimulate the production of antibodies and it is also and this is the most important thing that it is safer to use, especially if it is required to prolong the treatment period, this is confirmed by histopathological examination for Liver and small intestine tissue samples collected from all mice within the different groups.